In another study, co-targeting mTOR with cetuximab, a monoclonal antibody targeting EGFR that acts upstream of both Akt and ERK pathway, prevented the growth of HNSCC tumor xenografts by decreasing cell proliferation and lymphangiogenesis [90]. Here, EGFR is linked to head and neck squamous cell carcinoma.